Fig. 2: Kaplan-Meier estimates of PFS. | Nature Medicine

Fig. 2: Kaplan-Meier estimates of PFS.

From: Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial

Fig. 2

a–c, PFS in all treated patients (a), in patients who were TAP ≥1% and TAP <1% (b) and in patients who were TAP ≥5% and TAP <5% (c). One patient had no tissue available for central laboratory evaluation of PD-L1 expression; local laboratory results showed the patient’s tumor was PD-L1 low according to the 22C3 assay.

Back to article page